Biocytogen’s Post

🌟 Mark Your Calendar! Webinar on Expanding Tumor Antigen Targeting with TCR-Mimic Antibodies 🌟

Do you have efficient in vitro methods to measure the toxic effects of antibody-drug conjugates (ADCs) on cancer cells? We demonstrate the application of high-throughput flow cytometry, for evaluating the efficacy of ADCs that target the HER2 protein on cancer cells. Watch now to view the following topics: ✔️ Assessing internalization of ADCs into cancer cells, a critical step for their therapeutic effect. ✔️ Evaluating the activation of natural killer cells, through measurement of activation marker expression and cytokine release, providing insight into the antibody-dependent cellular cytotoxicity (ADCC) triggered by the monoclonal antibodies in ADCs. ✔️ Analyzing the diverse ways in which ADCs act on tumor cells, using the distinctive bystander killing effect exhibited by Enhertu®️ (an anti-HER2 ADC) as an example. Watch the full webinar here: https://ow.ly/ckN550SizaJ #highthroughput #cytometry #TumorDestruction #Cytotoxicity #cancercells #monoclonalantibody #immunotherapy #cancerresearch #highthroughputscreening

How do you assess the internalization of ADCs into cancer cells? Kirsty McBain from Sartorius examines the effectiveness of antibody-drug conjugates (ADCs) that target the HER2 protein on cancer cells using both traditional 2D monolayer cultures and the more intricate 3D tumor spheroids. Watch now for details of: 1️⃣ Evaluating the activation of natural killer cells, through measurement of activation marker expression and cytokine release, provides insight into the antibody-dependent cellular cytotoxicity (ADCC) triggered by the monoclonal antibodies in ADCs. 2️⃣ Assessing the internalization of ADCs into cancer cells - a critical step for their therapeutic effect. 3️⃣ Analyzing the diverse ways in which ADCs act on tumor cells, using the distinctive bystander killing effect exhibited by Enhertu®️ (an anti-HER2 ADC) as an example. Watch now: https://ow.ly/bOcf50SizcS #highthroughput #cytometry #TumorDestruction #Cytotoxicity #cancercells #monoclonalantibody #immunotherapy #cancerresearch #highthroughputscreening

🔬 Advancing Cancer Immunotherapy: YH006 – A Next-Gen CTLA-4×OX40 Treg Antagonist 🧬 Tumor-infiltrating regulatory T cells (Tregs) are key drivers of tumor progression, contributing to resistance against current immunotherapies by suppressing anti-tumor immune responses. While antibodies targeting CTLA-4—a molecule critical for regulating Treg activity—such as Ipilimumab have shown promise, their effectiveness is often limited by significant immune-related adverse events, particularly when combined with PD-1 inhibitors. Biocytogen’s YH006, a next-generation Fc-enhanced CTLA-4×OX40 bispecific antibody, offers a novel solution. Both targets are highly expressed on tumor-infiltrating Tregs. Designed in a 1:1 monovalent format for each target, YH006 reduces overall avidity for cells with low CTLA-4 and OX40 expression while increasing affinity for Tregs in tumor-infiltrating lymphocytes that co-express high levels of these markers. This design has the potential to enhance anti-tumor activity while mitigating immune-related toxicity. Contact us to learn more! #CancerResearch #Immunotherapy #BispecificAntibodies #TregDepletion #TumorMicroenvironment #DrugDevelopment #Biocytogen #Innovation

Continuing our series on FDA-approved antibodies, this week we focus on Bevacizumab (Avastin), approved in 2004. 🔬 Antibody type: Humanized IgG1 💊 Brand name: Avastin 🏢 Company: Genentech 🎯 First indication: Colorectal cancer Bevacizumab is a pioneering therapy that targets vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels. By inhibiting VEGF, Avastin effectively starves tumors of the blood supply they need to grow and spread. This innovative approach has made Bevacizumab a cornerstone in the treatment of several types of cancer, including metastatic colorectal cancer and non-small cell lung cancer. Its ability to inhibit angiogenesis has opened new avenues in cancer therapy. Join us next week, as we continue to explore groundbreaking FDA-approved antibodies! #AntibodyOfTheWeek #FDAApproved #MonoclonalAntibodies #CancerTreatment #AngiogenesisInhibition #Biotechnology #MedicalInnovation

We have a treat in store for you. Kirsty McBain from Sartorius demonstrates the application of high-throughput flow cytometry, in evaluating the efficacy of antibody-drug conjugates (ADCs) that target the HER2 protein in cancer cells. Watch now for information on: ☑️ Assessing the internalization of ADCs into cancer cells, a critical step for their therapeutic effect. ☑️ Evaluating the activation of natural killer cells, through measurement of activation marker expression and cytokine release, provides insight into the antibody-dependent cellular cytotoxicity (ADCC) triggered by the monoclonal antibodies in ADCs. ☑️ Analyzing the diverse ways in which ADCs act on tumor cells, using the distinctive bystander killing effect exhibited by Enhertu®️ (an anti-HER2 ADC) as an example. Watch now: https://ow.ly/bOcf50SizcS #highthroughput #cytometry #TumorDestruction #Cytotoxicity #cancercells #monoclonalantibody #immunotherapy #cancerresearch #highthroughputscreening

I came across a recent paper published by a group of scientists at Bayer, in which the team has developed BAY-405, a potent and selective MAP4K1 inhibitor, enhancing T-cell antitumor activity. This novel compound shows promise both as a standalone treatment and in combination with PD-1/PD-L1 blockers, offering new hope for cancer patients. Kudos to Team Bayer for their commitment to advancing the immuno-oncology field. Read the full article here: https://lnkd.in/ePxFz2iG #CancerResearch #Immunotherapy #OncologyInnovation

🌟 Excited to share our latest research article on the role of PPARδ inhibition in regulating PD-L1 expression in colorectal cancer cells! Key Highlights 🔬 Targeting Immune Checkpoints: The PPARδ antagonist GSK0660 significantly reduces PD-L1 expression, restoring the immune system's ability to recognize and attack tumor cells. 💡 Mechanistic Insights: We demonstrated that PPARδ directly regulates the PD-L1 promoter, enhancing its transcriptional activity. GSK0660 reverses this effect, suggesting its role as a potential therapeutic agent in overcoming immune evasion. 🧪 Preclinical Validation: In PPARδ-overexpressing colorectal cancer models, GSK0660 successfully decreased PD-L1 levels and enhanced T-cell activity, indicating its therapeutic potential. 📊 Future Directions: These findings open doors for PPARδ-targeted therapies in combination with checkpoint inhibitors to improve immunotherapy outcomes in colorectal cancer. 📖 Read the full article here: https://lnkd.in/dRhgVSVg #CancerResearch #PPARδInhibition #PDL1 #Immunotherapy #ColorectalCancer

Learn about the current trends and innovative approaches in cancer immunotherapy in this review paper. Immunotherapy has become a well-known and promising therapeutic approach in the field of cancer treatment. As a #tumor progresses, tumor cells employ various immune-regulatory mechanisms to suppress immune responses within the tumor #microenvironment. Using our understanding of these mechanisms, cancer #immunotherapy has been developed to enhance the immune system’s effectiveness in treating cancer. Numerous cancer immunotherapies are currently in clinical use, yet many others are either in different stages of development or undergoing clinical studies. This review paper in AAPS PharmSciTech discusses the features and current status of #cancer immunotherapies. This includes the application of monoclonal #antibodies, immune #checkpoint inhibitors, adoptive #cell therapy, #cytokine therapy, cancer #vaccines, and #gene therapy. Additionally, this paper also discusses limitations that may hinder successful clinical utilization and promising strategies, such such as combining immunotherapy with #nanotechnology. @Jaechang Kim RUBY MAHARJAN Jonghyuck Park American Association of Pharmaceutical Scientists (AAPS) | @aapscomms Bill Williams Daniel Davis, Ph.D., PharmD Johana Suh Michael Repka Claudio Salomon QI (Tony) ZHOU Sanyog Jain

#WeeklyCustomerPublication The efficacy of #immunotherapy can be improved by sweetening it up! Immunotherapy using anti-PD1 antibody targets PD-1 receptor on the surface of #immune cells to enhance their ability to recognize and eliminate #cancer cells. Due to its impressive durable effects in some cancer patients, it has become a new standard of care across many cancer indications. 🔔 However, for most solid tumors, the objective response rate to the anti-PD1 treatment alone is still below 30%. To improve the penetration of the anti-PD1 in solid tumor #microenvironment, a team of chemists and clinicians worked together to use a novel #glycoengineering platform to conjugate iRGD cyclic peptide to the antibody. The antibody conjugate was shown to effectively reach the tumor tissue microenvironment and engage tumor cells with tumor-specific T cells. #singlecellsequencing revealed remodeling of the TME and expansion of tumor-specific TILs expressing stem- and memory-associated genes. This bispecific antibody-peptide conjugate proves to be a potential novel approach to improve immunotherapy efficacy in solid tumors. Our Singleron #GEXSCOPE Single Cell RNA-seq Kit was used in this study. Read the full article here➡ https://lnkd.in/euKRsQ-s